Insulin Delivery Market Size Worth USD 41.31 Billion in 2030 - By Emergen Research

The insulin delivery market has been growing rapidly in recent years, driven by the increasing prevalence of diabetes and the rising demand for efficient insulin delivery systems. Insulin is a hormone produced by the pancreas that helps regulate blood sugar levels. For individuals with diabetes, insulin therapy is essential to manage their condition and prevent long-term complications. The global insulin delivery market size reached USD 17.80 billion in 2021 and is expected to register a revenue CAGR of 9.9% during the forecast period, according to the latest analysis by Emergen Research.

The growing prevalence of diabetes is one of the key drivers of the insulin delivery market. According to the International Diabetes Federation (IDF), there were approximately 463 million adults living with diabetes in 2019, and this number is expected to increase to 700 million by 2045. The increasing prevalence of diabetes has led to a rise in demand for insulin delivery systems, which can help patients manage their condition more effectively.

In addition to the growing prevalence of diabetes, there are several other drivers of the insulin delivery market. One of these is the increasing adoption of advanced insulin delivery systems, such as insulin pumps and pens, which offer greater convenience and precision compared to traditional insulin delivery methods. Insulin pumps, for example, can provide continuous insulin infusion and allow patients to adjust their insulin dose as needed. Insulin pens, on the other hand, are easy to use and allow patients to administer insulin discreetly in public settings.

To avail Sample Copy of the report @ https://www.emergenresearch.com/request-sample/1432

Despite the many drivers of the insulin delivery market, there are also several factors that are restraining its growth. One of these is the high cost of insulin and insulin delivery systems, which can be a barrier to access for some patients. Additionally, the lack of awareness and education about diabetes and insulin therapy in some regions can limit the adoption of advanced insulin delivery systems.

Despite these challenges, there are several growth factors that are expected to drive the insulin delivery market in the coming years. One of these is the increasing adoption of telemedicine and remote monitoring technologies, which can help improve access to diabetes care and allow for more personalized insulin therapy. Additionally, the development of novel insulin delivery systems, such as implantable pumps and inhalable insulin, is expected to create new opportunities for growth in the market.

Major Companies and Competitive Landscape:
The insulin delivery market is highly competitive, with several companies offering a range of insulin delivery systems to meet the needs of patients with diabetes. Some of the key players in the market include Medtronic, Novo Nordisk, Eli Lilly and Company, Sanofi, and F. Hoffmann-La Roche Ltd.

Medtronic is a leading player in the insulin delivery market, offering a range of insulin pumps, continuous glucose monitoring systems, and other diabetes management products. The company's MiniMed series of insulin pumps are widely used by patients with diabetes, and its Guardian Connect continuous glucose monitoring system allows patients to monitor their blood glucose levels in real-time.

Novo Nordisk is another major player in the insulin delivery market, with a strong focus on insulin pens and other injection devices. The company's NovoPen series of insulin pens are widely used by patients with diabetes, and its FlexTouch pen allows patients to administer insulin with a single button press.

Eli Lilly and Company is also a major player in the insulin delivery market, offering a range of insulin pens and other injection devices. The company's KwikPen and Humalog U-200 KwikPen are popular among patients with diabetes, and its recently launched Lyumjev insulin also offers a faster onset of action compared to traditional insulin formulations.

Sanofi is a global pharmaceutical company that offers a range of insulin delivery systems, including insulin pens, pumps, and inhalable insulin. The company's SoloStar and ClikSTAR insulin pens are widely used by patients with diabetes, and its Afrezza inhalable insulin offers an alternative to traditional insulin injections.

F. Hoffmann-La Roche Ltd is a Swiss multinational healthcare company that offers a range of insulin delivery systems, including insulin pumps, continuous glucose monitoring systems, and other diabetes management products. The company's Accu-Chek series of blood glucose meters and insulin pumps are popular among patients with diabetes, and its Senseonics Eversense continuous glucose monitoring system offers long-term monitoring of blood glucose levels.

In addition to these major players, there are several other companies competing in the insulin delivery market, including Tandem Diabetes Care, Insulet Corporation, and Ypsomed AG. These companies offer a range of insulin pumps, injection devices, and other diabetes management products to meet the needs of patients with diabetes.

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/1432

Segmentation Insights for Insulin Delivery Market:
The global insulin delivery market is projected to experience significant growth in the coming years, with increasing prevalence of diabetes and advancements in insulin delivery technology driving demand. The market can be segmented based on diabetes type, device type, route of administration, end-use, and sales channel.

In terms of diabetes type, the market can be divided into type 1 diabetes, type 2 diabetes, gestational diabetes, and prediabetes. Type 2 diabetes is expected to dominate the market in terms of revenue, owing to its high prevalence worldwide. However, the market for type 1 diabetes is also expected to grow, with increasing diagnosis rates and advancements in insulin pumps and continuous glucose monitoring systems.

Based on device type, the market can be segmented into insulin syringes, insulin pens (disposable and reusable), insulin jet injectors, insulin pumps (tethered and patch), insulin needles (standard and safety), insulin inhalers, implantable insulin, and others. Insulin pens are expected to dominate the market in terms of revenue, owing to their ease of use and portability. However, insulin pumps and continuous glucose monitoring systems are expected to experience the fastest growth, as they offer more precise insulin dosing and glucose monitoring.

The market can also be segmented based on route of administration, including oral/buccal, nasal, subcutaneous, transdermal, and others. The subcutaneous route is expected to dominate the market, owing to its widespread use in insulin injections and pumps. However, advancements in transdermal insulin delivery technology are expected to drive growth in this segment in the coming years.

In terms of end-use, the market can be segmented into hospitals, clinics, ambulatory care centers, and homecare. Homecare is expected to dominate the market, owing to increasing adoption of insulin pumps and continuous glucose monitoring systems by patients with diabetes. However, hospitals and clinics are also expected to experience significant growth, as they continue to be the primary sources of insulin administration for many patients.

Finally, the market can be segmented based on sales channel, including hospital pharmacies, retail pharmacies, online pharmacies, and others. Retail pharmacies are expected to dominate the market, owing to their widespread availability and convenience. However, online pharmacies are expected to experience significant growth, as they offer a wider range of products and lower prices.

Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/insulin-delivery-market

Eric Lee
Corporate Sales Specialist
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions.

This release was published on openPR.